Adicet Bio Inc Cash Flow Conversion Efficiency
Adicet Bio Inc cash flow conversion efficiency. Based on the latest financial reports, Adicet Bio Inc (ACET) has a cash flow conversion efficiency ratio of -0.165x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.82 Million) by net assets ($120.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Adicet Bio Inc (2008–2025)
Cash flow conversion efficiency of Adicet Bio Inc from 2008 to 2025. This chart illustrates how Adicet Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ACET stock price and chart for real-time trading data and today's change.
Adicet Bio Inc Cash Flow Conversion Ratio Explained
Adicet Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Adicet Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adicet Bio Inc ranked by their cash flow conversion efficiency. Also see ACET company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stadlauer Malzfabrik Aktiengesellschaft
VI:STM
|
N/A |
|
Ashley Services Group Ltd
AU:ASH
|
0.022x |
|
Leon Fuat Bhd
KLSE:5232
|
0.044x |
|
Intellinetics Inc
NYSE MKT:INLX
|
0.118x |
|
Bubang Co. Ltd
KQ:014470
|
0.043x |
|
Uniti SA
PA:ALUNT
|
-0.156x |
|
Satria Mega Kencana Tbk PT
JK:SOTS
|
-0.009x |
|
Cantex Mine Development Corp
V:CD
|
-1.416x |
Annual Cash Flow Conversion Efficiency for Adicet Bio Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Adicet Bio Inc from 2008 to 2025. Review cash generation quality of Adicet Bio Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $159.21 Million | $-95.25 Million | -0.598x | -20.85% |
| 2024-12-31 | $186.61 Million | $-92.38 Million | -0.495x | +10.11% |
| 2023-12-31 | $170.18 Million | $-93.72 Million | -0.551x | -259.64% |
| 2022-12-31 | $292.34 Million | $-44.77 Million | -0.153x | +9.08% |
| 2021-12-31 | $303.13 Million | $-51.05 Million | -0.168x | +55.49% |
| 2020-12-31 | $109.83 Million | $-41.55 Million | -0.378x | -181.91% |
| 2019-12-31 | $-60.37 Million | $-27.88 Million | 0.462x | +364.74% |
| 2018-12-31 | $104.20 Million | $-18.18 Million | -0.174x | +24.96% |
| 2017-12-31 | $49.69 Million | $-11.55 Million | -0.232x | -948.40% |
| 2016-12-31 | $304.44 Million | $8.34 Million | 0.027x | -72.20% |
| 2015-12-31 | $254.21 Million | $25.06 Million | 0.099x | -9.63% |
| 2014-12-31 | $233.58 Million | $25.48 Million | 0.109x | -10.55% |
| 2013-12-31 | $194.64 Million | $23.73 Million | 0.122x | +54.37% |
| 2012-12-31 | $168.00 Million | $13.27 Million | 0.079x | -18.90% |
| 2011-12-31 | $144.15 Million | $14.04 Million | 0.097x | +178.13% |
| 2010-12-31 | $124.35 Million | $-15.50 Million | -0.125x | -169.42% |
| 2009-12-31 | $125.38 Million | $22.51 Million | 0.180x | +44.01% |
| 2008-12-31 | $123.67 Million | $15.42 Million | 0.125x | -- |
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops … Read more